Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients.

Dufour A, Palermo G, Zellmeier E, Mellert G, Duchateau-Nguyen G, Schneider S, Benthaus T, Kakadia PM, Spiekermann K, Hiddemann W, Braess J, Truong S, Patten N, Wu L, Lohmann S, Dornan D, GuhaThakurta D, Yeh RF, Salogub G, Solal-Celigny P, Dmoszynska A, Robak T, Montillo M, Catalano J, Geisler CH, Weisser M, Bohlander SK.

Blood. 2013 May 2;121(18):3650-7. doi: 10.1182/blood-2012-10-458695. Epub 2013 Mar 22.

2.

Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.

Zenz T, Häbe S, Denzel T, Mohr J, Winkler D, Bühler A, Sarno A, Groner S, Mertens D, Busch R, Hallek M, Döhner H, Stilgenbauer S.

Blood. 2009 Sep 24;114(13):2589-97. doi: 10.1182/blood-2009-05-224071. Epub 2009 Jul 30.

3.

miR-34a as part of the resistance network in chronic lymphocytic leukemia.

Zenz T, Mohr J, Eldering E, Kater AP, Bühler A, Kienle D, Winkler D, Dürig J, van Oers MH, Mertens D, Döhner H, Stilgenbauer S.

Blood. 2009 Apr 16;113(16):3801-8. doi: 10.1182/blood-2008-08-172254. Epub 2008 Oct 21.

4.

Altered miRNA and gene expression in acute myeloid leukemia with complex karyotype identify networks of prognostic relevance.

Rücker FG, Russ AC, Cocciardi S, Kett H, Schlenk RF, Botzenhardt U, Langer C, Krauter J, Fröhling S, Schlegelberger B, Ganser A, Lichter P, Zenz T, Döhner H, Döhner K, Bullinger L.

Leukemia. 2013 Feb;27(2):353-61. doi: 10.1038/leu.2012.208. Epub 2012 Jul 19.

PMID:
22810507
5.

17p13/TP53 deletion in B-CLL patients is associated with microRNA-34a downregulation.

Dijkstra MK, van Lom K, Tielemans D, Elstrodt F, Langerak AW, van 't Veer MB, Jongen-Lavrencic M.

Leukemia. 2009 Mar;23(3):625-7. doi: 10.1038/leu.2008.264. Epub 2008 Sep 25. No abstract available.

PMID:
18818704
6.

miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities.

Mraz M, Malinova K, Kotaskova J, Pavlova S, Tichy B, Malcikova J, Stano Kozubik K, Smardova J, Brychtova Y, Doubek M, Trbusek M, Mayer J, Pospisilova S.

Leukemia. 2009 Jun;23(6):1159-63. doi: 10.1038/leu.2008.377. Epub 2009 Jan 22. No abstract available.

PMID:
19158830
7.

Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling.

Chiaretti S, Tavolaro S, Marinelli M, Messina M, Del Giudice I, Mauro FR, Santangelo S, Piciocchi A, Peragine N, Truong S, Patten N, Ghia EM, Torrente I, De Propris MS, Nanni M, Lawrence J, Guarini A, Foà R.

Genes Chromosomes Cancer. 2011 Apr;50(4):263-74. doi: 10.1002/gcc.20852. Epub 2011 Jan 13.

PMID:
21319261
8.

MicroRNA-223 expression is uniformly down-regulated in B cell lymphoproliferative disorders and is associated with poor survival in patients with chronic lymphocytic leukemia.

Zhou K, Yi S, Yu Z, Li Z, Wang Y, Zou D, Qi J, Zhao Y, Qiu L.

Leuk Lymphoma. 2012 Jun;53(6):1155-61. doi: 10.3109/10428194.2011.642303. Epub 2012 Jan 31.

PMID:
22145958
9.

TP53 mutation and survival in chronic lymphocytic leukemia.

Zenz T, Eichhorst B, Busch R, Denzel T, Häbe S, Winkler D, Bühler A, Edelmann J, Bergmann M, Hopfinger G, Hensel M, Hallek M, Döhner H, Stilgenbauer S.

J Clin Oncol. 2010 Oct 10;28(29):4473-9. doi: 10.1200/JCO.2009.27.8762. Epub 2010 Aug 9.

PMID:
20697090
10.

The prognostic significance of TP53 mutations in Chinese patients with chronic lymphocytic leukemia is independent of del(17p13).

Dong HJ, Zhou LT, Zhu DX, Wang DM, Fang C, Zhu HY, Zhuang Y, Miao KR, Xu W, Li JY.

Ann Hematol. 2011 Jun;90(6):709-17. doi: 10.1007/s00277-010-1125-8. Epub 2010 Nov 27.

PMID:
21113594
11.

The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype.

Dicker F, Herholz H, Schnittger S, Nakao A, Patten N, Wu L, Kern W, Haferlach T, Haferlach C.

Leukemia. 2009 Jan;23(1):117-24. doi: 10.1038/leu.2008.274. Epub 2008 Oct 9.

PMID:
18843282
12.

Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia.

Fabbri M, Bottoni A, Shimizu M, Spizzo R, Nicoloso MS, Rossi S, Barbarotto E, Cimmino A, Adair B, Wojcik SE, Valeri N, Calore F, Sampath D, Fanini F, Vannini I, Musuraca G, Dell'Aquila M, Alder H, Davuluri RV, Rassenti LZ, Negrini M, Nakamura T, Amadori D, Kay NE, Rai KR, Keating MJ, Kipps TJ, Calin GA, Croce CM.

JAMA. 2011 Jan 5;305(1):59-67. doi: 10.1001/jama.2010.1919.

13.

Present status and perspectives in functional analysis of p53 in chronic lymphocytic leukemia.

de Viron E, Michaux L, Put N, Bontemps F, Van Den Neste E.

Leuk Lymphoma. 2012 Aug;53(8):1445-51. doi: 10.3109/10428194.2012.660630. Epub 2012 Mar 1. Review.

PMID:
22280536
14.

Prognostic significance of ATM and TP53 deletions in Chinese patients with chronic lymphocytic leukemia.

Xu W, Li JY, Wu YJ, Yu H, Shen QD, Li L, Fan L, Qiu HX.

Leuk Res. 2008 Jul;32(7):1071-7. Epub 2007 Nov 26.

PMID:
18035414
15.

TP53 Mutations are infrequent in newly diagnosed chronic lymphocytic leukemia.

Zainuddin N, Murray F, Kanduri M, Gunnarsson R, Smedby KE, Enblad G, Jurlander J, Juliusson G, Rosenquist R.

Leuk Res. 2011 Feb;35(2):272-4. doi: 10.1016/j.leukres.2010.08.023. Epub 2010 Sep 25.

PMID:
20870288
16.

A comprehensive study of TP53 mutations in chronic lymphocytic leukemia: Analysis of 1287 diagnostic and 1148 follow-up CLL samples.

Pekova S, Mazal O, Cmejla R, Hardekopf DW, Plachy R, Zejskova L, Haugvicova R, Jancuskova T, Karas M, Koza V, Smolej L, Bezdickova L, Kozak T.

Leuk Res. 2011 Jul;35(7):889-98. doi: 10.1016/j.leukres.2010.12.016. Epub 2011 Jan 13.

PMID:
21232794
17.

p53 protein expression in chronic lymphocytic leukemia.

Sellmann L, Carpinteiro A, Nückel H, Scholtysik R, Siemer D, Klein-Hipass L, Kube D, Dürig J, Dührsen U, Stanelle J, Küppers R.

Leuk Lymphoma. 2012 Jul;53(7):1282-8. doi: 10.3109/10428194.2011.654115. Epub 2012 Feb 13.

PMID:
22220854
18.

MicroRNAs in chronic lymphocytic leukemia pathogenesis and disease subtypes.

Mraz M, Pospisilova S, Malinova K, Slapak I, Mayer J.

Leuk Lymphoma. 2009 Mar;50(3):506-9. doi: 10.1080/10428190902763517.

PMID:
19347736
19.

Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia.

Malcikova J, Stano-Kozubik K, Tichy B, Kantorova B, Pavlova S, Tom N, Radova L, Smardova J, Pardy F, Doubek M, Brychtova Y, Mraz M, Plevova K, Diviskova E, Oltova A, Mayer J, Pospisilova S, Trbusek M.

Leukemia. 2015 Apr;29(4):877-85. doi: 10.1038/leu.2014.297. Epub 2014 Oct 28.

20.

Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.

Farooqui MZ, Valdez J, Martyr S, Aue G, Saba N, Niemann CU, Herman SE, Tian X, Marti G, Soto S, Hughes TE, Jones J, Lipsky A, Pittaluga S, Stetler-Stevenson M, Yuan C, Lee YS, Pedersen LB, Geisler CH, Calvo KR, Arthur DC, Maric I, Childs R, Young NS, Wiestner A.

Lancet Oncol. 2015 Feb;16(2):169-76. doi: 10.1016/S1470-2045(14)71182-9. Epub 2014 Dec 31.

Supplemental Content

Support Center